Stockreport

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide [Yahoo! Finance]

Skye Bioscience, Inc.  (SKYE) 
PDF Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone duri [Read more]